InvestorsHub Logo
Followers 2531
Posts 69888
Boards Moderated 0
Alias Born 07/30/2012

Re: WoollenBlock48 post# 2363

Wednesday, 07/05/2017 11:10:24 PM

Wednesday, July 05, 2017 11:10:24 PM

Post# of 2812
$IDXG Latest Insider Purchases and Institutional Ownerships:

2016-02-03 Glorikian Harry Director Acquired 127,696
2016-02-03 KEEGAN JOSEPH D Director Acquired 127,696
2016-02-03 STOVER JACK E Interim President and CEO Director Acquired 294,756
2016-02-03 SULLIVAN STEPHEN J Director Acquired 295,656
2017-06-23 SC 13G ARMISTICE CAPITAL, LLC Acquired 965,784

John P. Dugan (Founder): 4,869,878 common shares

Other Insiders Approximately: 2,672,149 shares collectively

Total Insiders: 7,542,027 shares

Institutional Ownership: 30.6% 5.5 mil shares (Increased to 6.5 mil as of June 23rd)


Largest Institutional Holder: Heartland Advisors: 2,994,313


Recent News Headlines:

2017-06-28 Interpace Diagnostics Announces National Contract With Aetna

2017-06-26 Interpace Diagnostics Announces Coverage Of Thyroid Test By Premera Blue Cross

2017-06-16 Interpace Diagnostics Announces Pricing Of $13.7 Million Underwritten Public Offering Of Common Stock And Common Warrants

2017-06-06 Interpace Diagnostics Announces Agreement With Einstein Medical Center Of Philadelphia

2017-05-25 Interpace Diagnostics Announces Launch Of Enhancement To Thyroid Testing Services

2017-05-16 Interpace Diagnostics Group's (IDXG) CEO Jack Stover on Q1 2017 Results - Earnings Call Transcript

2017-05-15 Interpace Diagnostics To Host Conference Call And Webcast To Discuss First Quarter 2017 Financial Results On Monday May 15, 2017

2017-05-10 Interpace Diagnostics Presents New Data on PancraGEN® at DDW

2017-04-20 Interpace Diagnostics Eliminates Long Term Secured Debt

2017-04-18 Interpace Diagnostics Announces Coverage Of ThyraMIR With UnitedHealthcare

2017-04-13 Interpace Diagnostics Announces Receipt of Letter From Nasdaq Confirming Compliance With Minimum Stockholders' Equity Requirement

2017-04-04 A Look at Interpace Diagnostics Financials, Drug Pipeline and Market Opportunity

2017-04-03 Interpace Diagnostics Announces European Patent Approval For Underlying Technology Of Its Thyramir Microrna Classifier

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IDXG News